UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

Current Report Pursuant

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) November 5, 2014

 


 

HOLOGIC, INC.

(Exact Name of Registrant as Specified in Its Charter)

 


 

DELAWARE

(State or Other Jurisdiction of Incorporation)

 

     
1-36214   04-2902449
(Commission File Number)   (I.R.S. Employer Identification No.)

 

     
35 Crosby Drive, Bedford, MA   01730
(Address of Principal Executive Offices)   (Zip Code)

 

(781) 999-7300

(Registrant’s Telephone Number, Including Area Code)

 

 

(Former Name or Former Address, if Changed Since Last Report)


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 


 
 

  

Item 2.02 Results of Operations and Financial Condition.

 

On November 5, 2014, Hologic, Inc. issued a press release announcing its financial results for the fourth quarter and year ended September 27, 2014. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.

 

Limitation on Incorporation by Reference.  The information furnished in this Item 2.02, including the press release attached hereto as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as set forth by specific reference in such a filing.  

 

Cautionary Note Regarding Forward-Looking Statements. Except for historical information contained in the press release attached as an exhibit hereto, the press release contains forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these statements. Please refer to the cautionary note in the press release regarding these forward-looking statements.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Attached hereto are the current forms of (1) annual stock option award agreement and (2) annual performance stock unit award agreement, each as approved by the Compensation Committee.

 

A copy of each form is attached to this report as Exhibits 10.1 and 10.2 and is incorporated herein in its entirety by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

     
Exhibit
Number
  Description
10.1   Form of Annual Stock Option Award Agreement (adopted fiscal 2015).
10.2   Form of Performance Stock Unit Award Agreement (adopted fiscal 2015).
99.1  

Press release dated November 5, 2014 of Hologic, Inc. announcing its financial results for the fourth quarter and year ended September 27, 2014.

 

     

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   
Date: November 5, 2014 HOLOGIC, INC.
   
  By:  /s/ Robert W. McMahon   
    Robert W. McMahon
Chief Financial Officer

 

 

 

 

Exhibit 10.1

 

 

Notice of Grant of Stock Options

And Option Agreement

Hologic, Inc.

ID: 04-2902449

35 Crosby Drive

Bedford, MA 01730

 

 

 

   
Participant Name Plan: 2008 Equity Incentive Plan (the “Plan”)  
 

 

 

 
     
 

 

 

Effective Grant Date , you have been granted a Non-Qualified Stock Option (the “Option”) to buy shares granted shares of Hologic, Inc. (the “Company”) common stock at grant price . The Option is granted pursuant to the terms and conditions of the Plan, referenced above, and the option agreement (the “Option Agreement”) provided herewith.

 

Subject to the terms and conditions of the Option Agreement and the Plan, the Option will vest 20% on each of the first five anniversaries of the grant date, such that the Option will be fully vested on the fifth anniversary of the grant date. Unless sooner terminated pursuant to the terms of the Option Agreement or the Plan the Option will expire on Expiration Date [10 years after grant date] .

 

By your signature and the Company's signature below, you and the Company agree that the Option is granted under and governed by the terms and conditions of the Plan and the Option Agreement.

 

 

 

   
       
Hologic, Inc. Date
   
       
Electronic Signature Acceptance Date

 

- 1 -
 

 

HOLOGIC, INC.

 

NON-QUALIFIED STOCK OPTION AGREEMENT

 

 

Non Qualified Stock Option Agreement (the “Option Agreement”) pursuant to the Hologic, Inc. 2008 Equity Incentive Plan, as it may be amended from time to time (the “Plan”).

 

W I T N E S S E T H :

 

WHEREAS, the Company and the Optionee desire to enter into an agreement whereby the Company will grant the Optionee an option (the “Option”) to purchase shares of the Company’s Common Stock, $.01 par value per share (the “Common Stock”), as set forth in the Notice of Grant of Stock Options to which this Award Agreement is attached (the “Award Notice”); and

 

WHEREAS, this Option is intended to qualify as a “Non-Qualified Stock Option”, which is a stock option which does not qualify as an incentive stock option under Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”).

 

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and the Optionee agree as follows:

 

1. Grant of Option .

 

Pursuant to the terms and conditions of this Option Agreement and the Plan (which is incorporated herein by reference), the Company hereby grants to the Optionee an Option to purchase shares of Common Stock (the “Option Shares”) as provided in the Award Notice. The exercise price at which the Option Shares may be purchased (the “Option Exercise Price”) and the vesting schedule of the Option are set forth in the Award Notice. The number and class of securities, vesting schedule and exercise price per share subject to this Option are subject to adjustment as set forth in the Plan. In the event of a conflict between the terms and conditions of the Plan and this Option Agreement, the terms and conditions of the Plan shall prevail. Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Plan.

 

2. Vesting of Option .

 

Subject to the provisions of the Plan, Section 3 of this Option Agreement and the right of the Company to accelerate the date upon which any or all of this Option would otherwise become exercisable, the Optionee shall be entitled to exercise this Option with respect to all or a portion of the percentage or number of the Option Shares provided in the Award Notice. Notwithstanding the foregoing, in the event that the Optionee’s Service (as defined below) is terminated as a result of the death or Permanent Disability (as defined in Section 23(e)(3) of the Code) of the Optionee, the Option shall become fully vested upon such termination . For purposes of this Agreement, the term “Service” shall mean service as a Service Provider to the Company, and the term “Service Provider” shall mean an employee, officer or director of the Company or an Affiliate of the Company, or a consultant currently providing services to the Company or an Affiliate of the Company. Whether a termination of Service shall have occurred for purposes of this Agreement shall be determined by the Company, which determination shall be final, binding and conclusive.

  

Notwithstanding any provision of this Option Agreement to the contrary, in no event may this Option be exercised after the Expiration Date set forth in the Award Notice.

 

3. Termination of Service.

 

If the Optionee’s Service is terminated (a “Termination”), then unless otherwise provided in this Option Agreement or the Plan, this Option may be exercised as to all shares with respect to which Optionee could exercise this Option on the date of Termination, and which shares have not been previously purchased, until the earlier of the Expiration Date, or:

 

(i) in the case of a Termination by reason of death or Permanent Disability, one year after such Termination; and
(ii) in all other cases, ninety (90) days after the Termination; or

 

such other date as determined by the Company, and there shall be no further vesting of the Option after such Termination.

 

Notwithstanding the foregoing, in the case of a Termination for cause, the ability to exercise this Option may be terminated on such earlier date as the Company may specify, and such date may be set so as to prevent the Optionee from further exercising any portion of this Option.

 

- 2 -
 

  

4. Nontransferability; Persons Able to Exercise .

 

The Option may not be transferred other than by will or the laws of descent and distribution. During the life of the Optionee, only the Optionee may exercise this Option. If the Optionee dies while still employed by the Company, or the periods specified in Section 3, this Option may be exercised by the Optionee’s executors, administrators, legatees or distributees, provided that such person or persons comply with the provisions of this Option applicable to the Optionee.

 

5. Method of Exercising Option .

 

The Option may be exercised, in whole or in part, by written notice to the Company, containing an executed Notice of Exercise in the form of Attachment A, provided that the Company, in its discretion, may modify or augment these requirements as provided in Section 7 of this Option Agreement, or where appropriate because a person other than the Optionee is exercising the Option pursuant to Section 4. The written notice specified in this Section must be accompanied by payment of the Option Exercise Price for the shares being purchased. Payment shall be made in cash, unless the Company, in its sole discretion, authorizes payment to be made in shares of Common Stock of the Company, a combination of such shares and cash. As soon as practical after receipt of this notice and payment, the Company shall deliver the purchased Option Shares. In the event this Option is exercised by any person other than the Optionee, the notice shall be accompanied by appropriate proof of the right of such person to exercise this Option.

 

 

6. No Rights Other Than Those Expressly Created .

 

Neither this Option, the Option Agreement nor any action taken hereunder shall be construed as (i) giving the Optionee any right to be retained in the Service of, or continue to be affiliated with, the Company, (ii) giving the Optionee any equity or interest of any kind in any assets of the Company, or (iii) creating a trust of any kind or a fiduciary relationship of any kind between the Optionee and the Company. As to any claim for any unpaid amounts under this Option, any person having a claim for payments shall be an unsecured creditor. The Optionee shall not have any of the rights of a stockholder with respect to any Option Shares until such time as this Option has been exercised and Option Shares have been issued.

 

7. Compliance with Laws .

 

(a) Withholding of Taxes . Pursuant to applicable federal, state, local or foreign laws, the Company may be required to collect or withhold income or other taxes from Optionee upon the grant of this Option, the exercise of this Option, or at some other time. The Company may require, as a condition to the exercise of this Option, or demand, at such other time as it may consider appropriate, that the Optionee pay the Company the amount of any taxes which the Company may determine is required to be collected or withheld, and the Optionee shall comply with the requirement or demand of the Company.

 

- 3 -
 

 

(b) Securities Law Compliance . Upon exercise (or partial exercise) of this Option, the Optionee shall make such representations and furnish such information as may, in the opinion of counsel for the Company, be appropriate to permit the Company to issue or transfer the Option Shares in compliance with the provisions of applicable federal or state securities laws. The Company, in its discretion, may postpone the issuance and delivery of Option Shares upon any exercise of this Option until completion of such registration or other qualification of such shares under any federal or state laws, or stock exchange listing, as the Company may consider appropriate. In addition, the Company may require that prior to the issuance or transfer of Option Shares upon exercise of this Option, the Optionee enter into a written agreement to comply with any restrictions on subsequent disposition that the Company deems necessary or advisable under any applicable federal and state securities laws. The Option Shares issued hereunder may be legended to reflect such restrictions.

 

(c) General . No Option Shares shall be issued upon exercise of this Option unless and until the Company is satisfied, in its sole discretion, that there has been compliance with all legal requirements applicable to the issuance of such Option Shares.

 

 

8. Miscellaneous .

 

(a) Non-Qualified Option . The Option hereby granted is not intended to be an “incentive stock option” as that term is defined in Section 422 of the Internal Revenue Code.

 

(b). Recoupment/Claw-Back of Awards . Notwithstanding any other provision of this Option Agreement to the contrary, any Option granted under this Option Agreement (including any proceeds, gains or other economic benefit actually or constructively received upon any receipt or exercise of any Option or upon the receipt or resale of any share of Common Stock underlying the Option) shall be subject to the terms of any compensation recoupment or claw-back policy implemented by the Company, as any such policy may be amended from time to time, and/or subject to recoupment as required by any other provisions of any law (including, without limitation, Section 10D of the Securities Exchange Act of 1934, as amended), government regulation or stock exchange listing requirement.

 

(c) Discretion of the Committee . Unless otherwise explicitly provided herein, the Board of Directors of the Company, or an authorized committee thereof, shall make all determinations required to be made hereunder, including determinations required to be made by the Company, and shall interpret all provisions of this Option and Option Agreement, as it deems necessary or desirable, in its sole and unfettered discretion. Such determinations and interpretations shall be binding on and conclusive to the Company and the Optionee.

  

(d) Amendment . This Option may only be modified or amended by a writing signed by both parties.

 

(e) Notices . Any notices required to be given under this Option shall be sufficient if in writing and if sent by certified mail, return receipt requested, and addressed as follows:

 

if to the Company:

 

Hologic, Inc.

35 Crosby Dr.

Bedford, MA 01730

Attention: Chief Financial Officer

 

if to the Optionee:

 

As set forth in the records of the Company

 

or to such other address as either party may designate under the provisions hereof.

 

(f) Entire Agreement . This Option Agreement shall supersede in its entirety all prior undertakings and agreements of the Company and Optionee, whether oral or written, with respect to this option; provided however that nothing herein shall supersede any prior written employment or other similar written agreement, if any, that may provide, in certain circumstances, for acceleration or extension of options granted to the Optionee.

 

- 4 -
 

 

(g) Successors and Assigns . The rights and obligations of the Company under this Option Agreement shall inure to the benefit of and be binding upon the successors and assigns of the Company.

 

(h) Applicable Law; Severability . All rights and obligations under this Option Agreement shall be governed by the laws of the State of Delaware. In the event that any court of competent jurisdiction shall determine that any provision, or any portion thereof, contained in this Option Agreement shall be unenforceable in any respect, then such provision shall be deemed limited to the extent that such court deems it enforceable, and as so limited shall remain in full force and effect. In the event that such court shall deem any such provision, or portion thereof, wholly unenforceable, the remaining provisions of this Option Agreement shall nevertheless remain in full force and effect. 

 

(i) Paragraph Headings; Rules of Construction . The paragraph headings used in this Option Agreement are for convenience of reference, and are not to be construed as part of this Option or Option Agreement. The parties hereto acknowledge and agree that the rule of construction to the effect that any ambiguities are resolved against the drafting party shall not be employed in the interpretation of this Option Agreement.

 

(j) Electronic Copies . The Company may choose to deliver certain materials relating to the Plan in electronic form. By accepting this option, you consent and agree that the Company may deliver the Plan prospectus and the Company’s annual report to you in an electronic format. If at any time you would prefer to receive paper copies of these documents, as you are entitled to, the Company would be pleased to provide you with such copies upon request.

 

(k). No Waiver of Rights, Powers and Remedies . No failure or delay by a party hereto in exercising any right, power or remedy under this Option Agreement, and no course of dealing between the parties hereto, shall operate as a waiver of any such right, power or remedy of the party, unless explicitly provided for herein. No single or partial exercise of any right, power or remedy under this Option Agreement by a party hereto, nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder.

 

(l). Counterparts . The Award Notice to which this Option Agreement is attached and incorporated by reference may be executed in multiple counterparts, including by electronic or facsimile signature, each of which shall be deemed in original but all of which together shall constitute one and the same instrument.

 

- 5 -

 

Exhibit 10.2 

 

 

Notice of Grant of Performance Stock Units
and Performance Stock Unit Award Agreement

Hologic, Inc.

ID: 04-2902449

35 Crosby Drive

Bedford, MA 01730 

 

 

 

   
Grantee Name

Plan: 2008 Equity Incentive
Plan
(the “Plan”)
 

 

 

 
     
 

 

Effective GRANT DATE (the “Grant Date”), you (the “Grantee”) have been granted an award of a target number of SHARES GRANTED performance stock units (“PSUs”) of Hologic, Inc. (the “Company”) (such number of PSUs are hereinafter referred to as the “Target Number of PSUs”) . The PSUs are granted pursuant to the terms and conditions of the Plan, referenced above, and the performance stock unit award agreement (the “PSU Award Agreement”) provided herewith.

 

Subject to the terms and conditions of the PSU Award Agreement and the Plan, and achievement of the performance targets set forth in the [20XX] Long-Term Performance Program (the “[20XX] LTP Overview”), the PSUs will vest on the third anniversary of the Grant Date, entitling you to receive one share of the Company’s common stock for each PSU so vested.

 

By your signature and the Company's signature below, you and the Company agree that these PSUs are granted under and governed by the terms and conditions of the Plan and the PSU Award Agreement.

 

 

 

   
       
Hologic, Inc. Date
   
       
Electronic Signature Acceptance Date

  

 
 

 

Hologic, Inc.

Performance Stock Unit Award Agreement

 

 

Performance Stock Unit Award Agreement (the “PSU Award Agreement”) pursuant to the Hologic, Inc. 2008 Equity Incentive Plan, as it may be amended from time to time (the “Plan”).

W I T N E S S E T H :

 

WHEREAS, the Company and the Grantee desire to enter into an agreement whereby the Company will grant the Grantee Performance Stock Units (“PSUs”) in respect of the Company’s Common Stock, $.01 par value per share (the “Common Stock”), as set forth in the Notice of Grant of Performance Stock Units to which this PSU Award Agreement is attached (the “Award Notice”).

 

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and the Grantee agree as follows:

 

1. Grant of PSUs . Pursuant to the terms and conditions of this PSU Award Agreement and the Plan (which is incorporated herein by reference), the Company hereby grants to the Grantee an award for the Target Number of PSUs as provided in the Award Notice. The shares of Common Stock covered by these PSUs are sometimes hereinafter referred to as the “PSU Shares.” The number and class of securities and vesting schedule of the PSUs are subject to adjustment as set forth in this PSU Award Agreement, the Plan and the [20XX] LTP Overview (which is incorporated herein by reference). In the event of a conflict between the terms and conditions of the Plan and this PSU Award Agreement, the terms and conditions of the Plan shall prevail. Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Plan.

 

2. Performance Stock Units . Each PSU entitles the Grantee to receive from the Company (i) one share of Common Stock for each PSU vested as of a Vesting Date (as defined below) and (ii) the right to receive notional dividend equivalents, if any, each in accordance with the terms of and subject to adjustment as provided in this PSU Award Agreement, the Plan and the [20XX] LTP Overview. After a Vesting Date, and subject to the terms and conditions of this Agreement, the Company shall deliver the PSU Shares which have vested on that date. To the extent that the PSUs granted hereby are not otherwise forfeited, the number of PSUs that vest shall be rounded to the nearest whole PSU.

 

3. Dividend Equivalents . Until the Vesting Date, whenever dividends are paid or distributed with respect to the Common Stock, the Grantee shall be entitled to receive notional dividend equivalents (the “Dividend Equivalents”) in an amount equal in value to the amount of the dividend or property distributed on a single share of Common Stock as of the record date for such dividend or distribution, multiplied by the number of PSUs granted hereunder that are vested as of the Vesting Date. Payment of the notional dividend equivalents paid on PSUs will be withheld by the Company and shall be delivered to the Grantee as of the Vesting Date, if and only to the extent that the PSUs have vested as of said date, as set forth in paragraph 4.

 

4. Vesting .

 

(a) Subject to achievement of the performance targets set forth in the [20XX] LTP Overview, and except as otherwise set forth herein, the PSUs granted hereby will vest on the third anniversary of the Grant Date as provided in the Award Notice, provided that the Grantee has remained in continuous Service (as defined below) through such date (the “Restriction Lapse Date”). The calculation of the number of PSUs, if any, that will vest on the Restriction Lapse Date is specified in the [20XX] LTP Overview and is based upon (a) the Company achieving each of the three Annual ROIC Thresholds (as set forth in the [20XX] LTP Overview) and (b) the Three-Year Average ROIC (as set forth in the [20XX] LTP Overview). If, for any fiscal year during the Performance Period (as defined below), the Company does not achieve the applicable Annual ROIC Threshold the PSUs granted or otherwise eligible to be issued hereunder shall be forfeited as of the last day of the applicable fiscal year. If the Company does not achieve the Minimum Three-Year Average ROIC (as set forth in the [20XX] LTP Overview) during the Performance Period, the PSUs granted or otherwise eligible to be issued hereunder shall be forfeited as of the last day of the Performance Period. For purposes of this PSU Award Agreement, the term “Service” shall mean service as a Service Provider to the Company; and the term “Service Provider” shall mean an employee, officer or director of the Company or an Affiliate of the Company or a consultant currently providing services to the Company or an Affiliate of the Company. Whether a termination of Service shall have occurred for purposes of this PSU Award Agreement shall be determined by the Company, which determination shall be final, binding and conclusive. If the Grantee’s Service is terminated prior to the Restriction Lapse Date, then the unvested PSUs shall terminate and Grantee shall have no further rights hereunder, including without limitation any rights to receive any Dividend Equivalents as set forth in paragraph 3, with respect to such unvested PSUs. For purposes of this PSU Award Agreement, the term “Performance Period” shall be the period commencing on September [XX], [20XX] (the first day of the Company’s current fiscal year) and ending on September [XX], [20XX] (the last day of the Company’s fiscal year [20XX]).

 

 
 

 

(b) Notwithstanding anything to the contrary in Section 4(a) above and subject to the conditions set forth below, the Target Number of PSUs granted hereby will vest prior to the Restriction Lapse Date upon the termination of the Grantee’s Service as a result of the death or Permanent Disability (as defined in Section 22(e)(3) of the Code) of the Grantee, provided that the Grantee has remained in continuous Service through the date of termination, and the Company has not failed to achieve any of the Annual ROIC Thresholds or the Minimum Three-Year Average ROIC for any fiscal year or Performance Period, as applicable, ended prior to the date of termination (the “Termination Vesting Date”).

 

(c) Notwithstanding anything to the contrary in Section 4(a) above and subject to the conditions set forth below, if the Company consummates a Change of Control prior to the Restriction Lapse Date, the Target Number of PSUs granted hereby will vest on the earlier to occur of (i) the Restriction Lapse Date or (ii) upon termination of the Grantee’s employment during the Change of Control Period either (A) by the Company other than for Cause or (B) by the Grantee for Good Reason, provided that in the case of clause (i) the Grantee has remained in continuous Service through the Restriction Lapse Date, and in the case of clause (ii)(A) or (ii)(B) the Grantee has remained in continuous Service through the date of termination, and in each such case (clause (i), clause (ii)(A) or clause (ii)(B)) the Company has not failed to achieve any of the Annual ROIC Thresholds or the Minimum Three-Year Average ROIC for any fiscal year or Performance Period, as applicable, ended prior to the date of the Change of Control (the “Change of Control Vesting Date” and each of the Restriction Lapse Date, the Termination Vesting Date, and the Change of Control Vesting Date a “Vesting Date”). For the avoidance of doubt, the effect of the foregoing is that upon the occurrence of a Change of Control prior to the Restriction Lapse Date, the Target Number of PSUs granted hereby that have not otherwise been forfeited prior to the Change of Control shall in effect become time-lapsed restricted stock units (“RSUs”) for shares of the Company’s Common Stock at a rate of one RSU for each of the Target Number of PSUs. Certain capitalized terms used in this paragraph (c) are defined in Annex A. Notwithstanding anything to the contrary in this PSU Award Agreement (including the foregoing, the [20XX] LTP Overview, or Annex A hereto), if the Grantee is a party to a prior written employment agreement, change of control agreement or other similar written agreement (each a “Prior Agreement”), that provides, in certain circumstances, for greater benefits regarding the accelerated vesting of equity awards (including PSUs) following a change of control of the Company or similar transaction, the terms of such Prior Agreement shall control the definition of the term “Change of Control” (or any term used therein of similar import), and the terms and conditions by which the vesting of the PSUs may be accelerated as a result of a Change of Control, as well as the benefits that may otherwise be available to the Grantee upon a Change of Control. For the avoidance of doubt, the parties hereby confirm that the PSUs granted hereunder shall be considered and treated as restricted stock under any such Prior Agreement for purposes of determining whether any such vesting is accelerated.

 

5. Nontransferability . The PSUs granted pursuant to this PSU Award Agreement may not be transferred without the consent of the Company, other than by will or the laws of descent and distribution.

 

6. No Rights Other Than Those Expressly Created . Neither this PSU Award Agreement, the PSUs, nor any action taken hereunder shall be construed as (i) giving the Grantee any right to be retained in the Service of, or continue to be affiliated with, the Company, (ii) giving the Grantee any equity or interest of any kind in any assets of the Company, or (iii) creating a trust of any kind or a fiduciary relationship of any kind between the Grantee and the Company. As to any claim for any unpaid amounts or distributions under this PSU Award Agreement, any person having a claim for payments shall be an unsecured creditor. The Grantee shall not have any of the rights of a stockholder with respect to any PSU Shares or any Dividend Equivalents until such time as the underlying PSU has been vested and the PSU Shares have been issued.

 

 
 

 

7. Compliance with Laws .

 

(a) Withholding of Taxes . Pursuant to applicable federal, state, local or foreign laws, the Company may be required to collect or withhold income or other taxes from Grantee upon a Vesting Date or at some other time. The Company may require, upon a Vesting Date, or demand, at such other time as it may consider appropriate, that the Grantee pay the Company the amount of any taxes which the Company may determine is required to be collected or withheld, and the Grantee shall comply with the requirement or demand of the Company.

 

(b) Section 280G . In the event that the Grantee shall become entitled to payments and/or benefits provided by this PSU Award Agreement or any other amounts in the “nature of compensation” as a result of a Change of Control (the “Company Payments”), and such Company Payments will be subject to the excise tax (the “Excise Tax”) imposed by Section 4999 of the Code or similar provision, then, except as may otherwise be provided in a Prior Agreement between the Company and the Grantee, the amounts of any Company Payments shall be automatically reduced to an amount one dollar less than the amount that would subject the Grantee to the Excise Tax.

 

(c) Securities Law Compliance . Upon vesting (or partial vesting) of the PSUs granted hereunder, the Grantee shall make such representations and furnish such information as may, in the opinion of counsel for the Company, be appropriate to permit the Company to issue or transfer the PSU Shares in compliance with the provisions of applicable federal or state securities laws. The Company, in its discretion, may postpone the issuance and delivery of PSU Shares until completion of such registration or other qualification of such shares under any federal or state laws, or stock exchange listing, as the Company may consider appropriate. In addition, the Company may require that prior to the issuance or transfer of PSU Shares, the Grantee enter into a written agreement to comply with any restrictions on subsequent disposition that the Company deems necessary or advisable under any applicable federal and state securities laws. The PSU Shares issued hereunder may be legended to reflect such restrictions.

 

(d) General . No PSU Shares shall be issued or Dividend Equivalents distributed upon vesting of a PSU granted hereunder unless and until the Company is satisfied, in its sole discretion, that there has been compliance with all legal requirements applicable to the issuance of such PSU Shares and/or distribution of such Dividend Equivalents.

 

8. Miscellaneous .

 

(a) 409A Compliance . The Company may, in its sole and absolute discretion, delay payments hereunder or make such other modifications with respect to the issuance of stock hereunder as it reasonably deems necessary to comply with Section 409A of the Code and interpretative guidance thereunder.

 

(b) Recoupment/Claw-Back of Awards . Notwithstanding any other provision of this PSU Award Agreement to the contrary, any PSU granted under this PSU Award Agreement (including any proceeds, gains or other economic benefit actually or constructively received upon any receipt or exercise of any PSU or upon the receipt or resale of any share of Common Stock underlying the PSU) shall be subject to the terms of any compensation recoupment or claw-back policy implemented by the Company, as any such policy may be amended from time to time, and/or subject to recoupment as required by any other provisions of any law (including, without limitation, Section 10D of the Securities Exchange Act of 1934, as amended), government regulation or stock exchange listing requirement.

 

 
 

 

(c) Discretion of the Committee . Unless otherwise explicitly provided herein, the Board of Directors of the Company, or an authorized committee thereof, shall make all determinations required to be made hereunder, including but not limited to determinations relating to the achievement of any thresholds or the vesting of any PSUs hereunder, and shall interpret all provisions of this PSU Award Agreement and the underlying PSUs, as it deems necessary or desirable, in its sole and absolute discretion. Such determinations and interpretations shall be binding on and conclusive to the Company and the Grantee. Without limiting the foregoing, the Company may, in its sole and absolute discretion, delay payments hereunder or make such other modifications with respect to the issuance of stock hereunder as it reasonably deems necessary to the extent that (a) audited financials are not complete for any applicable period during the Performance Period and/or (b) that the Company has not had an adequate opportunity to review the audited financials or calculate the ROIC, the Three-Year Average ROIC, or any other metric set forth in the [20XX] LTP Overview, for any applicable period during the Performance Period.

 

(d) Amendment . This PSU Award Agreement may only be modified or amended by a writing signed by both parties.

 

(e) Notices . Any notices required to be given under this PSU Award Agreement shall be sufficient if in writing and if sent by certified mail, return receipt requested, and addressed as follows:

 

if to the Company:

 

Hologic, Inc.

35 Crosby Dr.

Bedford, MA 01730

Attention: Chief Financial Officer

 

if to the Grantee:

 

As set forth in the records of the Company

 

or to such other address as either party may designate under the provisions hereof.

 

(f) Entire Agreement . This PSU Award Agreement shall supersede in its entirety all prior undertakings and agreements of the Company and the Grantee, whether oral or written, with respect to the PSUs granted hereunder; provided, however, that nothing herein shall supersede any Prior Agreement that may provide, in certain circumstances, for greater benefits regarding acceleration of vesting of equity awards granted to the Grantee.

 

(g) Successors and Assigns . The rights and obligations of the Company under this PSU Award Agreement shall inure to the benefit of and be binding upon the successors and assigns of the Company.

 

(h) Applicable Law; Severability . All rights and obligations under this PSU Award Agreement shall be governed by the laws of the State of Delaware. In the event that any court of competent jurisdiction shall determine that any provision, or any portion thereof, contained in this PSU Award Agreement shall be unenforceable in any respect, then such provision shall be deemed limited to the extent that such court deems it enforceable, and as so limited shall remain in full force and effect. In the event that such court shall deem any such provision, or portion thereof, wholly unenforceable, the remaining provisions of this PSU Award Agreement shall nevertheless remain in full force and effect. 

 

(i) Paragraph Headings; Rules of Construction . The paragraph headings used in this PSU Award Agreement are for convenience of reference, and are not to be construed as part of this PSU Award Agreement. The parties hereto acknowledge and agree that the rule of construction to the effect that any ambiguities are resolved against the drafting party shall not be employed in the interpretation of this PSU Award Agreement.

 

 
 

 

(j) Electronic Copies . The Company may choose to deliver certain materials relating to the Plan in electronic form. By accepting this PSU Award Agreement, the Grantee consents and agrees that the Company may deliver the Plan prospectus and the Company’s annual report to Grantee in an electronic format. If at any time Grantee would prefer to receive paper copies of these documents, the Company will provide such copies upon request.

 

(k) No Waiver of Rights, Powers and Remedies . No failure or delay by a party hereto in exercising any right, power or remedy under this PSU Award Agreement, and no course of dealing between the parties hereto, shall operate as a waiver of any such right, power or remedy of the party, unless explicitly provided for herein. No single or partial exercise of any right, power or remedy under this PSU Award Agreement by a party hereto, nor any abandonment or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other or further exercise thereof or the exercise of any other right, power or remedy hereunder.

 

(l) Counterparts . The Award Notice to which this PSU Award Agreement is a part may be executed in multiple counterparts, including by electronic or facsimile signature, each of which shall be deemed in original but all of which together shall constitute one and the same instrument.

 

 
 

 

Annex A

Certain Definitions Regarding Accelerated Vesting on a Change of Control

 

Certain Definitions. For purposes of the Performance Stock Unit Award Agreement to which this Annex is attached (the “PSU Award Agreement”), the following capitalized terms shall have the meanings set forth below.

 

(a) “ Cause ” means a determination by the Company that any of the following has occurred: (i) disloyalty, gross negligence, willful misconduct or breach of fiduciary duty to the Company which results in substantial direct or indirect loss, damage or injury to the Company; (ii) the Grantee’s material violation of the Company’s Code of Conduct, and other Company Codes of Conduct or other policies and procedures that are applicable to the Grantee; (iii) the commission, indictment, plea of nolo contendere or conviction of the Grantee of a felony; (iv) the breach of the Grantee’s confidentiality, non-competition, non-solicitation covenants set forth in a separate written agreement between the Company and the Grantee; (v) a violation of federal or state securities law or regulations; or (vi) any other act or omission by the Grantee that would constitute “cause” under any employment or similar agreement entered into between the Grantee and the Company or any of its subsidiaries.

 

(b) “ Change of Control ” means:

 

(i) The acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 50% or more of the Voting Stock of the Company; provided, however, that any acquisition by the Company, or any employee benefit plan (or related trust) of the Company of 50% or more of Voting Stock shall not constitute a Change in Control; and provided, further, that any acquisition by a corporation with respect to which, following such acquisition, more than 50% of the then outstanding shares of common stock of such corporation, is then beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial owners of the Voting Stock immediately prior to such acquisition in substantially the same proportion as their ownership, immediately prior to such acquisition, of the Voting Stock, shall not constitute a Change in Control; or

 

(ii) Any transaction which results in the Continuing Directors (as defined in the Certificate of Incorporation of the Company) constituting less than a majority of the Board of Directors of the Company; or

 

(iii) The consummation of (A) a Merger with respect to which the individuals and entities who were the beneficial owners of the Voting Stock immediately prior to such Merger do not, following such Merger, beneficially own, directly or indirectly, more than 50% of the then outstanding shares of common stock of the corporation resulting from the Merger (the Resulting Corporation”) as a result of the individuals’ and entities’ shareholdings in the Company immediately prior to the consummation of the Merger and without regard to any of the individual’s and entities’ shareholdings in the corporation resulting from the Merger immediately prior to the consummation of the Merger, (B) a complete liquidation or dissolution of the Company, or (C) the sale or other disposition of all or substantially all of the assets of the Company, excluding a sale or other disposition of assets to a subsidiary of the Company.

 

Notwithstanding the foregoing, no Change of Control shall be deemed to occur if as a result of any transaction referred to in paragraph (iii) above, the Company is deemed to be the accounting acquirer under U.S. generally accepted accounting principles pursuant to Accounting Standards Codification Topic 805, as it may be amended from time to time or any successor rule, standard, pronouncement, law or regulation.

 

(c) “ Change of Control Period ” means the period commencing upon a Change of Control and ending two (2) years after a Change of Control.

 

 
 

 

(d) “ Exchange Act ” means the Securities Exchange Act of 1934, as amended, and any successor act thereto.

 

(e) “ Good Reason ” means:

 

(i) A material diminution in the Grantee’s base compensation;

 

(ii) A material diminution in the Grantee’s authority, duties and responsibilities as in effect immediately prior to the Change of Control;

 

(iii) A material diminution in the authority, duties and responsibilities of the supervisor to whom the Grantee is required to report as in effect immediately prior to the Change of Control;

 

(iv) A material change in the geographic location in which Grantee’s principal office was located immediately prior to the Change of Control;

 

(v) A material diminution in the budget over which the Grantee had authority immediately prior to the of the Change of Control; and

 

(vi) Any other action or inaction that constitutes a material breach by the Company of the PSU Award Agreement or any other agreement under which the Grantee provides services;

 

provided, however, that Good Reason shall not exist unless the Grantee has given written notice to the Company within ninety (90) days of the initial existence of the Good Reason event or condition(s) giving specific details regarding the event or condition; and unless the Company has had at least thirty (30) days to cure such Good Reason event or condition after the delivery of such written notice and has failed to cure such event or condition within such thirty (30) day cure period.

 

(f) “ Merger ” means a reorganization, merger or consolidation.

 

(g) “ Voting Stock ” means the then outstanding shares of voting stock of the Company.

 

 

 

 

Hologic Announces Fourth Quarter Fiscal 2014 Operating Results

BEDFORD, Mass., Nov. 5, 2014 /PRNewswire/ -- Hologic, Inc. (NASDAQ: HOLX) announced today its results for the fourth fiscal quarter ended September 27, 2014.

Fourth Quarter Financial Highlights and Recent Developments:

  • Reported revenues of $660.6 million increased 6.2% compared to the prior year and included a one-time revenue benefit of $20.1 million related to an amended license agreement with Roka Bioscience.
  • Net of the one-time revenue benefit, revenues from the Company's underlying business were $640.5 million, an increase of 3.0%, with operational growth of 2.8%.
  • Revenues grew in all four business segments.
    • Diagnostics grew 2.4% (net of the one-time revenue benefit).
    • Breast Health grew 3.1%.
    • GYN Surgical grew 2.3%.
    • Skeletal Heath grew 10.4%.
  • Non-GAAP earnings per share (EPS) were $0.43, which included $0.05 from the one-time revenue benefit. Net of this one-time benefit, non-GAAP EPS was $0.38, a decline of 3.6% compared to the prior year, but above the guidance range of $0.36 to $0.37.
  • GAAP EPS was $0.10 per diluted share compared to a loss of $4.11 in the prior year.
  • Installed the 2,000th Hologic 3D mammography system worldwide and surpassed the fiscal 2014 U.S. placement goal.
  • On October 31, the Centers for Medicare and Medicaid Services (CMS) released reimbursement rates for 3D mammography screening and diagnostic services. The new rule also creates a pathway for private insurers to explore broader coverage and payment options.

"Our fourth quarter provides further evidence that our turnaround is strengthening and our outlook is improving," said Stephen MacMillan, President and Chief Executive Officer. "Although we began the year with declining performance, this quarter we achieved growth in all four franchises and transitioned to a company on a clear path to sustainable organic growth. While we still have work to do, we have put the pieces in place to drive accelerating growth and are much better positioned as we head into fiscal 2015."

Fourth Quarter Fiscal 2014 Revenue Overview by Segment (Compared to the Fourth Quarter Fiscal 2013):

  • Diagnostics revenues of $297.1 million increased 2.4%, net of the one time revenue benefit of $20.1 million. The increase was primarily due to an increase in the Company's molecular diagnostics franchise and blood screening franchise, primarily from the Japanese Red Cross deal. Partially offsetting these increases was a continued decrease in U.S. ThinPrep pap test sales due to interval expansion.
  • Breast Health revenues of $241.5 million increased 3.1% driven by strong growth in 3D mammography system sales, as well as service revenue growth from the growing installed base of digital mammography systems. Partially offsetting these increases was the expected overall sales decline of 2D mammography systems as customers continue to transition to the Company's 3D systems.
  • GYN Surgical revenues of $78.5 million increased 2.3%, driven by strong growth in worldwide MyoSure system sales, partially offset by declines of U.S. NovaSure system sales.
  • Skeletal Health revenues of $23.4 million increased 10.4%, driven by growing sales of the Company's new Horizon platform and to a lesser extent, an increase in mini C-arm system sales.

Financial Guidance:

The Company's guidance includes current operations, including revenues from its approved and cleared products. The fiscal 2015 growth rates exclude the one-time revenue benefit of $20.1 million in fiscal 2014.

Fiscal 2015 (Year Ending September 26, 2015)

The Company expects fiscal 2015:

  • Operational revenue growth, excluding the impact of foreign currency, of approximately 2% to 3.5% over fiscal 2014. Including an expected 1% negative impact from foreign currency, the Company expects reported growth of approximately 1% to 2.5%, resulting in reported revenues in the range of $2.54 billion to $2.57 billion. The Company expects growth in all four business segments, as well as internationally.
  • Non-GAAP EPS in the range of $1.50 to $1.54. Compared to $1.46 in fiscal 2014, this represents year-over-year growth of approximately 3% to 5.5%.

First Quarter Fiscal 2015 (Quarter Ending December 27, 2014)

The Company expects first quarter fiscal 2015:

  • Operational revenue growth, excluding the impact of foreign currency, of approximately 3% to 4.5% over the first quarter of fiscal 2014. Including an expected 1% negative impact from foreign currency, the Company expects reported growth of approximately 2% to 3.5%, resulting in reported revenues in the range of $625 million to $635 million.
  • Non-GAAP EPS in the range of $0.35 to $0.36. Compared to $0.34 in the first quarter of fiscal 2014, this represents year-over-year growth of approximately 3% to 6%.

Hologic may not generate expected revenues and may incur expenses or charges, realize income or gains, or execute transactions in fiscal 2015 that could cause actual results to vary from the guidance above. In addition, the Company is continuing to monitor the effects of the U.S., European and general worldwide economic and regulatory conditions and related uncertainties, including the implementation of healthcare cost containment measures and healthcare reform legislation, as well as foreign currency fluctuations, which, along with other uncertainties facing the Company's business including those referenced elsewhere herein and in its filings with the Securities and Exchange Commission, could adversely affect anticipated results.

The Company includes non-GAAP financial measures in this press release. Definitions of these non-GAAP financial measures and the reconciliations to the Company's comparable GAAP financial measures (calculated in accordance with U.S. generally accepted accounting principles) for the periods presented, are included in this press release.

Conference Call and Webcast:

Hologic's management will host a conference call on Wednesday, November 5, 2014, at 4:30 p.m. (Eastern) to discuss fourth quarter fiscal year 2014 operating results. Interested participants may listen to the call by dialing 877-718-5098 or 719-325-4925 for international callers and referencing participant code 5099577 15 minutes prior to the call. For those unable to participate in the live broadcast, a replay will be available two hours after the call ends through Wednesday, November 26, 2014, at 888-203-1112 or 719-457-0820 for international callers, access code 5099577. The Company will also provide a live webcast of the call. Interested participants may access the webcast on the Company's website at www.investors.hologic.com/investors-overview. A PowerPoint presentation related to the conference call will be posted to the site.

About Hologic, Inc.:

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The Company's core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research and development program, Hologic is dedicated to The Science of Sure. For more information on Hologic, visit www.hologic.com .

Hologic, 3D mammography, Aptima, Gen-Probe, Horizon, mini C-arm, MyoSure, NovaSure, and ThinPrep and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statement Disclaimer:

This News Release contains forward-looking information that involves risks and uncertainties, including statements about the Company's plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information included herein based upon or otherwise incorporating judgments or estimates relating to future performance, events or expectations; the Company's strategies, positioning, resources, capabilities, and expectations for future performance; and the Company's outlook and financial and other guidance. These forward-looking statements are based upon assumptions made by the Company as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.

Risks and uncertainties that could adversely affect the Company's business and prospects, and otherwise cause actual results to differ materially from those anticipated, include without limitation: the ability of the Company to successfully manage recent and ongoing leadership and organizational changes, including the ability of the Company to attract, motivate and retain key employees; U.S., European and general worldwide economic conditions and related uncertainties; the Company's reliance on third-party reimbursement policies to support the sales and market acceptance of its products, including the possible adverse impact of government regulation and changes in the availability and amount of reimbursement and uncertainties for new products or product enhancements; uncertainties regarding the recently enacted or future healthcare reform legislation, including associated tax provisions, or budget reduction or other cost containment efforts; changes in guidelines, recommendations and studies published by various organizations that could affect the use of the Company's products; uncertainties inherent in the development of new products and the enhancement of existing products, including FDA approval and/or clearance and other regulatory risks, technical risks, cost overruns and delays; the risk that products may contain undetected errors or defects or otherwise not perform as anticipated; risks associated with strategic alliances and the ability of the Company to realize anticipated benefits of those alliances; risks associated with acquisitions, including without limitation, the Company's ability to successfully integrate acquired businesses, the risks that the acquired businesses may not operate as effectively and efficiently as expected even if otherwise successfully integrated, the risks that acquisitions may involve unexpected costs or unexpected liabilities; the risks of conducting business internationally; the risk of adverse exchange rate fluctuations on the Company's international activities and businesses; manufacturing risks, including the Company's reliance on a single or limited source of supply for key components, and the need to comply with especially high standards for the manufacture of many of its products; the Company's ability to predict accurately the demand for its products, and products under development, and to develop strategies to address its markets successfully; the early stage of market development for certain of the Company's products; the Company's leverage risks, including the Company's obligation to meet payment obligations and financial covenants associated with its debt; risks related to the use and protection of intellectual property; expenses, uncertainties and potential liabilities relating to litigation, including, without limitation, commercial, intellectual property, employment and product liability litigation; technical innovations that could render products marketed or under development by the Company obsolete; and competition.

The risks included above are not exhaustive. Other factors that could adversely affect the Company's business and prospects are described in the filings made by the Company with the SEC. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

HOLOGIC, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(In millions except number of shares, which are reflected in thousands, and per share data)






Three Months Ended


Year Ended


September 27,
2014


September 28,
2013


September 27,
2014


September 28,
2013













Revenues :












Product

$

532.1



$

521.6



$

2,094.9



$

2,100.9


Service and other

128.5



100.5



435.8



391.4


Total revenues

660.6



622.1



2,530.7



2,492.3














Cost of revenues:












Product

182.0



201.0



731.3



818.2


Amortization of intangible assets

80.5



80.9



314.6



307.9


Impairment of intangible assets





26.6



1.7


Service and other

53.1



49.6



212.7



203.1


Total cost of revenues

315.6



331.5



1,285.2



1,330.9














Gross profit

345.0



290.6



1,245.5



1,161.4














Operating expenses:












Research and development

52.1



48.7



203.2



197.6


Selling and marketing

86.8



76.8



331.7



342.1


General and administrative

65.2



48.0



259.8



227.7


Amortization of intangible assets

28.8



26.7



113.8



112.6


Contingent consideration



(0.5)





91.3


Impairment of goodwill



1,117.4





1,117.4


Restructuring and divestiture charges

15.1



9.7



51.7



32.8


Impairment of intangible assets

5.1





5.6




Gain on sale of intellectual property







(53.9)














Total operating expenses

253.1



1,326.8



965.8



2,067.6














Income (loss) from operations

91.9



(1,036.2)



279.7



(906.2)














Other expense:












Interest expense

(52.4)



(65.8)



(220.6)



(281.1)


Other (expense) income, net

(0.8)



3.0



(3.6)



3.6


Debt extinguishment loss



(6.0)



(7.4)



(9.2)


Total other expense

(53.2)



(68.8)



(231.6)



(286.7)














Income (loss) before income taxes

38.7



(1,105.0)



48.1



(1,192.9)


Provision (benefit) for income taxes

10.5



8.9



30.8



(20.1)














Net income (loss)

$

28.2



$

(1,113.9)



$

17.3



$

(1,172.8)














Net income (loss) per common share:












Basic

$

0.10



$

(4.11)



$

0.06



$

(4.36)


Diluted

$

0.10



$

(4.11)



$

0.06



$

(4.36)














Weighted average number of shares outstanding:












Basic

277,855



270,867



275,499



268,704


Diluted

282,217



270,867



278,360



268,704


HOLOGIC, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In millions)






September 27, 2014


September 28, 2013

ASSETS












Current assets:






Cash and cash equivalents

$

741.6



$

829.4


Accounts receivable, net

396.0



409.3


Inventories

330.6



289.4


Deferred income taxes

39.4




Other current assets

58.2



96.1


Total current assets

1,565.8



1,624.2








Property, plant and equipment, net

461.9



491.5


Goodwill and intangible assets

6,244.4



6,721.2


Other assets

142.6



163.9


Total assets

$

8,414.7



$

9,000.8








LIABILITIES AND STOCKHOLDERS' EQUITY












Current liabilities :






Current portion of long-term debt

$

114.5



$

563.8


Accounts payable and accrued liabilities

354.2



392.3


Deferred revenues

150.9



132.3


Total current liabilities

619.6



1,088.4








Long-term debt, net of current portion

4,153.2



4,242.1


Deferred income taxes

1,375.4



1,535.3


Other long-term liabilities

203.5



193.5


Total liabilities

6,351.7



7,059.3


Total stockholders' equity

2,063.0



1,941.5


Total liabilities and stockholders' equity

$

8,414.7



$

9,000.8


HOLOGIC, INC.


RECONCILIATION OF GAAP REVENUES, EPS AND NET INCOME (LOSS) TO NON-GAAP REVENUES, EPS, NET INCOME AND ADJUSTED EBITDA


(Unaudited)


(In millions, except earnings per share)








Three Months Ended


Year Ended



September 27,
 2014


September 28,
 2013


September 27,
 2014


September 28,
 2013















Revenues:













GAAP revenues

$

660.6



$

622.1



$

2,530.7



$

2,492.3



Adjustment primarily related to blood screening collaboration







19.7


(1)

Non-GAAP revenues

$

660.6



$

622.1



$

2,530.7



$

2,512.0
















Earnings (loss) per share:













GAAP earnings (loss) per share - Diluted

$

0.10



$

(4.11)



$

0.06



$

(4.36)



Adjustment to net earnings (loss) (as detailed below)

0.33



4.50



1.45



5.86



Non-GAAP earnings per share – diluted

$

0.43



$

0.39



$

1.51



$

1.50


(2)














Net income (loss):













GAAP net income (loss)

$

28.2



$

(1,113.9)



$

17.3



$

(1,172.8)



Adjustments:













Contingent revenue primarily from blood screening collaboration







19.7


(1)

Amortization of intangible assets

109.3



107.6



428.4



420.5


(3)

Contingent consideration



(0.5)





91.3


(4)

Non-cash interest expense relating to convertible notes

8.7



11.8



37.1



52.7


(5)

Restructuring, divestiture and acquisition-related charges

16.5



20.7



66.5



62.7


(6)

Fair value adjustments

1.9



3.1



11.2



64.5


(7)

Gain on sale of intellectual property







(53.9)


(8)

Debt extinguishment and related charges



7.0



8.4



16.7


(9)

Impairment of goodwill



1,117.4





1,117.4


(10)

Impairment of intangible assets

5.1





32.2



1.7


(10)

Other charges (gains), net

3.7



(3.9)



11.3



(2.6)


(11)

Income tax effect of reconciling items

(53.4)



(41.7)



(192.7)



(211.4)


(12)

Non-GAAP net income

$

120.0



$

107.6



$

419.7



$

406.5
















Adjusted EBITDA:













Non-GAAP net income

$

120.0



$

107.6



$

419.7



$

406.5



Interest expense, net, not adjusted above

43.3



52.4



181.2



219.6



Provision for income taxes

63.9



50.6



223.5



191.3



Depreciation expense, not adjusted above

19.9



20.8



80.3



80.8



Adjusted EBITDA

$

247.1



$

231.4



$

904.7



$

898.2



Explanatory Notes to Reconciliations:

(1) To primarily reflect a fair value adjustment relating to contingent revenue earned and received post acquisition under the Company's blood screening collaboration, which was eliminated under purchase accounting.

(2) Non-GAAP earnings per share was calculated based on 282,217 and 273,925 weighted average diluted shares outstanding for the three months ended September 27, 2014 and September 28, 2013, respectively, and 278,360 and 271,869 weighted average diluted shares outstanding for the twelve months ended September 27, 2014 and September 28, 2013, respectively.

(3) To reflect a non-cash charge attributable to the amortization of intangible assets.

(4) To reflect a charge to operating expenses attributable to contingent consideration related to certain of the Company's acquisitions.

(5) To reflect certain non-cash interest expense related to amortization of the debt discount attributable to the equity conversion feature of the Company's convertible notes.

(6) To reflect restructuring and divestiture charges, as well as certain costs associated with the Company's acquisition(s) and integration plans, which primarily include retention costs, transfer costs, and asset impairments.

(7) To reflect non-cash fair value adjustments for: (i) additional depreciation expense in all periods presented related to the fair value write-up of fixed assets acquired from Gen-Probe; and (ii) write-up of inventory acquired from Gen-Probe and sold during the prior year period.

(8) To reflect a net gain resulting from a cash payment received in final settlement of an agreement, net of associated costs.

(9) To reflect a non-cash loss related to Credit Agreement amendments for those creditors who opted not to participate in the refinancing or for partial extinguishment related to voluntary prepayments, as well as related third-party transaction costs.

(10) To reflect a non-cash impairment charge for certain of the Company's intangible assets primarily related to the MRI breast coils product line to reflect fair value in fiscal 2014, and other charges related to developed technology in fiscal 2013, as well as a goodwill charge related to the Molecular Diagnostics franchise in fiscal 2013.

(11) To reflect the net impact from miscellaneous transactions during the period.

(12) To reflect an annual effective tax rate of 34.75% for the three and twelve months ended September 27, 2014 and an annual effective tax rate of 32.0% for the three and twelve months ended September 28, 2013 on a non-GAAP basis.

Future Non-GAAP Adjustments:

Future GAAP EPS may be affected by changes in ongoing assumptions and judgments relating to the Company's acquired businesses, and may also be affected by nonrecurring, unusual or unanticipated charges, expenses or gains, which are excluded in the calculation of the Company's non-GAAP EPS guidance as described in this press release. It is therefore not practicable to reconcile non-GAAP EPS guidance to the most comparable GAAP measure.

Use of Non-GAAP Financial Measures:

The Company has presented the following non-GAAP financial measures in this press release: revenues; net income; EPS; and adjusted EBITDA. The Company defines its non-GAAP revenues to primarily include contingent revenue earned post-acquisition under the blood screening collaboration which was eliminated under purchase accounting. The Company defines adjusted EBITDA as its non-GAAP net income plus net interest expense, income taxes, and depreciation and amortization expense included in its non-GAAP net income. The Company defines its non-GAAP net income and EPS to exclude: (i) the amortization of intangible assets; (ii) acquisition-related charges and effects, such as charges for contingent consideration, transaction costs, integration costs including retention, and credits and/or charges associated with the write-up of acquired inventory and fixed assets to fair value, and the effect of a reduction in revenue primarily related to contingent revenue under the blood screening collaboration, described above; (iii) non-cash interest expense related to amortization of the debt discount for convertible debt securities; (iv) restructuring and divestiture charges; (v) non-cash debt extinguishment losses and related transaction costs; (vi) litigation settlement charges (benefits); (vii) other-than-temporary impairment losses on investments; (viii) other one-time, nonrecurring, unusual or infrequent charges, expenses or gains that may not be indicative of the Company's core business results; and (ix) income taxes related to such adjustments.

The Company believes the use of non-GAAP financial measures is useful to investors by eliminating certain of the more significant effects of its acquisitions and related activities, non-cash charges resulting from the application of GAAP to convertible debt instruments with cash settlement features, charges related to debt extinguishment losses, investment impairments, litigation settlements, and restructuring and divestiture initiatives. These non-GAAP measures also reflect how Hologic manages its businesses internally. In addition to the adjustments set forth in the calculation of the Company's non-GAAP net income and EPS, its adjusted EBITDA eliminates the effects of financing, income taxes and the accounting effects of capital spending. As with the items eliminated in its calculation of non-GAAP net income, these items may vary for different companies for reasons unrelated to the overall operating performance of a company's business. When analyzing the Company's operating performance, investors should not consider these non-GAAP financial measures as a substitute for net income prepared in accordance with GAAP.

Contact:
Deborah R. Gordon
Vice President, Investor Relations and
Corporate Communications
(781) 999-7716
deborah.gordon@hologic.com